Keppra XR is expected to be available in US pharmacies at the end of September 2008.
The goal of therapy with antiepileptic drugs is freedom from seizures and minimal side effects, the company said.
Troy Cox, senior vice president of UCB, said: “This is one of many milestones at UCB to develop new treatment options for people with epilepsy. Keppra XR provides a way to simplify treatment and offers another chance to achieve seizure control, which is an important goal for patients living with epilepsy.”